Agios Pharmaceuticals
AGIO
155 hedge funds and large institutions have $1.42B invested in Agios Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 71 increasing their positions, 42 reducing their positions, and 22 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 42
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
4% more capital invested
Capital invested by funds: $1.36B → $1.42B (+$61.2M)
1% less funds holding
Funds holding: 156 → 155 (-1)
2% less call options, than puts
Call options by funds: $8.24M | Put options by funds: $8.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.7M |
| 2 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$12.1M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$11.9M |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$11.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$52.3M |
| 2 |
Millennium Management
New York
|
-$37.7M |
| 3 |
Jennison Associates
New York
|
-$15.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$10.1M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$5.68M |
AGIO Hedge Fund Activity: Q2 2016 in Review
155 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2016, worth a combined $1.42B — up 4.5% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new AGIO positions and 22 closed out — a net gain of 3 holders — while 71 added to existing stakes and 42 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $29.7M. The largest seller was Capital World Investors, cutting an estimated $52.3M.
- 155 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2016, down from 156 in Q1 2016.
- Funds reported $1.42B of Agios Pharmaceuticals stock for Q2 2016, up 4.5% quarter-over-quarter.
- 25 funds opened new Agios Pharmaceuticals positions in Q2 2016 and 22 closed out, a net change of +3 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2016 was T. Rowe Price Associates, an estimated $29.7M added.
- The largest Agios Pharmaceuticals seller in Q2 2016 was Capital World Investors, an estimated $52.3M sold.
Based on aggregated 13F filings for Q2 2016.